trending Market Intelligence /marketintelligence/en/news-insights/trending/entIOQI1RAzR0viwjB4Okg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Midatech Pharma brain cancer therapy gets US FDA orphan drug tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Midatech Pharma brain cancer therapy gets US FDA orphan drug tag

Midatech Pharma PLC said the U.S. Food and Drug Administration granted orphan drug status to MTX110, its investigational brain cancer therapy.

The Cardiff, U.K.-based company is developing MTX110 as a potential treatment for malignant glioma, a form of cancer that forms in the brain and spinal cord.

MTX110 is also intended to treat diffuse intrinsic pontine glioma, or DIPG, a rare and fatal type of childhood brain cancer. In DIPG, the fast-growing tumor forms in the brain stem and patients have an average life expectancy of seven to nine months.

Midatech is evaluating MTX110 in an ongoing combined early and mid-stage study involving patients with DIPG.

The company is also examining the drug in other brain cancer indications, including medulloblastoma — which is most common in children and young adults — and glioblastoma multiforme, a fast-growing type of the disease that occurs in adults.